Meeting
2015 ASCO Annual Meeting
Survival, biomarker, and toxicity analysis of nivolumab (NIVO) in patients that progressed on ipilimumab (IPI).
Authors
Jeffrey S. Weber
Moffitt Cancer Center, Tampa, FL
Jeffrey S. Weber , Geoffrey Thomas Gibney , Bin Yu , PingYan Cheng , Alberto J Martinez , Jodi Kroeger , Jillene Freed , Allison Richards , Xiuhua Zhao , Michael J. Schell
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Melanoma/Skin Cancers
Clinical Trial Registration Number
NCT01176461
Citation
J Clin Oncol 33, 2015 (suppl; abstr 9055)
DOI
10.1200/jco.2015.33.15_suppl.9055
Abstract #
9055
Poster Bd #
298
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Updated survival, toxicity, and biomarkers of nivolumab with/without peptide vaccine in patients naive to, or progressed on, ipilimumab (IPI).
First Author: Jeffrey S. Weber
Poster
2023 ASCO Annual Meeting
Nivolumab and ipilimumab in advanced non small cell lung cancer previously treated with PD1 axis inhibition.
First Author: Scott N. Gettinger
Poster
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
A phase II study of talimogene laherparepvec followed by talimogene laherparepvec + nivolumab in refractory T cell and NK cell lymphomas, cutaneous squamous cell carcinoma, Merkel cell carcinoma, and other rare skin tumors (NCI #10057).
First Author: Ann W. Silk
Poster
2017 Genitourinary Cancers Symposium
Evaluation of the clinical activity of ipilimumab (IPI) plus nivolumab (NIVO) in patients (pts) with NIVO-refractory metastatic urothelial cancer (UC).
First Author: Margaret K. Callahan